Court Rejects Challenge to Medicare Hemp Coverage Program

A federal judge has dismissed a lawsuit filed by anti-marijuana advocacy groups seeking to block a Medicare program that provides up to $500 annually in hemp-derived products for eligible beneficiaries.

U.S. District Court sided with the Centers for Medicare & Medicaid Services (CMS), rejecting arguments that the Trump administration initiative violated federal drug laws. The program, which launched earlier this year, primarily covers CBD products but extends to other hemp-derived compounds meeting federal guidelines.

The plaintiffs—a coalition of drug prevention organizations—argued the program conflicted with the Controlled Substances Act and exceeded CMS's regulatory authority. But the court found the agency acted within its discretion when implementing coverage for products legal under the 2018 Farm Bill.

The Program's Scope

The CMS initiative targets Medicare beneficiaries seeking alternatives for pain management, sleep disorders, and anxiety. Eligible patients can access the $500 benefit through participating pharmacies and licensed dispensaries that stock federally compliant hemp products.

CMS officials have emphasized the program focuses exclusively on products containing less than 0.3% THC—the legal threshold established by the Farm Bill. The agency developed strict testing and verification protocols to ensure compliance.

"This coverage option responds to growing demand from seniors exploring hemp-based wellness products," a CMS spokesperson said in court filings. "We've built safeguards to maintain federal compliance while expanding patient choice."

Industry Response

Hemp industry advocates celebrated the ruling as validation of the 2018 Farm Bill's intent to mainstream legal hemp commerce.

Jonathan Miller, general counsel for the U.S. Hemp Roundtable, called the decision "a significant win for the industry and Medicare patients seeking access to these products. The court recognized what we've maintained all along—legal hemp products belong in the healthcare system."

The ruling could accelerate similar coverage expansion in other federal health programs. Several state Medicaid agencies have inquired about parallel initiatives, according to industry sources familiar with the discussions.

CBD manufacturers reported increased interest from Medicare-eligible consumers since the program's announcement. Sales data from major retailers show double-digit growth in products marketed toward seniors, particularly tinctures and topicals formulated for pain relief.

Opposition's Arguments

The plaintiff organizations—including Smart Approaches to Marijuana (SAM) and several parent advocacy groups—contended the program would normalize cannabis use and potentially expose seniors to impaired products or misleading health claims.

Their legal challenge questioned whether CMS possessed authority to cover substances derived from Cannabis sativa, regardless of THC content. They also raised concerns about quality control and the lack of FDA-approved CBD medications beyond Epidiolex.

The court found these arguments unpersuasive, noting Congress explicitly legalized hemp through the Farm Bill and granted federal agencies discretion in implementing related programs.

What's Next

The dismissed lawsuit is unlikely to be the final word on federal coverage for hemp products. Policy experts suggest the ruling establishes important precedent but expect continued litigation as the regulatory framework evolves.

The plaintiff groups have 30 days to appeal the decision to the circuit court. Legal observers give an appeal modest chances of success given the district court's thorough analysis of statutory authority.

Meanwhile, CMS continues enrolling pharmacies and dispensaries in the program. The agency reported more than 2,000 participating locations across 45 states as of last month, with enrollment expanding weekly.

The program's first-year budget allocates $150 million for hemp product coverage, though actual utilization will determine whether Congress adjusts funding in future appropriations. Early enrollment data suggests demand may exceed initial projections, potentially requiring supplemental funding requests.

Hemp industry analysts project the Medicare program could drive $200-300 million in annual sales once fully implemented, representing roughly 3-5% of the total U.S. hemp-derived CBD market.

---

This article is based on original reporting by www.marijuanamoment.net.